Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : ALNY save search
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-10-25 (Crawled : 19:00) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: 0.4%
H: 1.29%
C: 1.29%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 1.43%
H: 0.64%
C: -0.09%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -1.28%
H: 0.58%
C: -1.46%
disease alzheimer’s positive results
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 22:00) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda positive treatment meeting
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.15%
H: 1.32%
C: -0.02%
positive treat risk topline hypertension cardiovascular results study
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | $894.265 -0.48% -0.48% 610K
|
Health Technology
|
| O: 0.05%
H: 1.33%
C: 0.38%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 5.53%
H: 5.23%
C: -2.49%
disease alzheimer’s positive results
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-04-26 (Crawled : 23:00) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
REGN | $894.265 -0.48% -0.48% 610K
|
Health Technology
|
| O: -0.99%
H: 0.38%
C: -0.48%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.76%
H: 0.33%
C: -1.54%
disease report alzheimer’s positive
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-04-26 (Crawled : 23:00) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
REGN | $894.265 -0.48% -0.48% 610K
|
Health Technology
|
| O: -0.99%
H: 0.38%
C: -0.48%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.76%
H: 0.33%
C: -1.54%
disease report alzheimer’s positive
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-09-08 (Crawled : 08:00) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -1.67%
H: 10.61%
C: 10.19%
positive results study
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-08-29 (Crawled : 13:00) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -1.08%
H: 0.0%
C: 0.0%
REGN | $894.265 -0.48% -0.48% 610K
|
Health Technology
|
| O: -0.64%
H: 1.24%
C: 0.07%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.56%
H: 1.41%
C: -0.34%
treatment nephropathy positive study phase 2
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-08-03 (Crawled : 12:00) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 47.44%
H: 0.0%
C: 0.0%
topline positive results study
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-06-09 (Crawled : 12:00) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 1.59%
H: 0.68%
C: -2.46%
treatment nephropathy topline positive phase 2
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published: 2022-01-21 (Crawled : 13:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -10.41%
H: 0.0%
C: 0.0%
positive results phase 3
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Published: 2021-11-05 (Crawled : 22:00) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -1.65%
H: 0.0%
C: 0.0%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
positive results positive results phase 3
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published: 2021-10-27 (Crawled : 21:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.42%
H: 0.24%
C: -3.2%
positive results topline phase 3
Alnylam Receives Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) for use of GIVLAARI for the Treatment of Acute Hepatic Porphyria (AHP) in Adults
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -2.37%
treatment positive drug technology hepatitis
Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
Published: 2021-08-05 (Crawled : 21:00) - biospace.com/
NVO | $123.45 -0.36% 0.03% 3M
|
Health Technology
|
| O: 3.16%
H: 1.88%
C: 1.77%
LLY | $746.74 -0.54% 1.01% 2.5M
|
Health Technology
|
| O: 0.31%
H: 0.85%
C: 0.35%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 0.2%
H: 5.7%
C: 5.5%
treatment positive results trial topline
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -4.18%
H: 1.62%
C: 1.41%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.11%
H: 0.09%
C: -3.66%
positive results phase 3
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
Published: 2021-04-19 (Crawled : 19:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.39%
H: 1.79%
C: -0.68%
positive results positive results phase 3
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published: 2021-01-07 (Crawled : 15:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 5.35%
H: 4.77%
C: 4.33%
positive results phase 3 topline
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.